Peptoon, Inc., established in 1997, is a South Korean biopharmaceutical company specializing in the development of peptide-based therapeutics. Based in Daejeon, the company focuses on creating innovative treatments for chronic diseases, including diabetes, cancer, and neurodegenerative disorders. In 2023, Peptoon reported revenues of approximately $5 million. The company invests significantly in R&D, aiming to advance its proprietary sustained-release technology for peptide drugs. Key products include PT320, a long-acting Exenatide for type 2 diabetes, and PT110, a potential treatment for Parkinson's disease. Peptoon collaborates with global partners to enhance its research capabilities and expand its market presence, committed to improving patient outcomes through innovative therapies.

SmartDepot™ : Peptron’s proprietary ultrasonic spray drying technology for the preparation of sustained release (SR) injectable microsphere formulation.

Public

Biotech, CDMO